Syncom Formulations (India) Ltd. is a key player in the pharmaceutical sector, known for its innovative products and cost-effective solutions. With a current share price of ₹20.12, the company holds promise for future growth. Here’s an in-depth analysis of its share price predictions from 2024 to 2040.
About Syncom Formulations
Syncom Formulations is an Indian pharmaceutical company specializing in manufacturing and marketing formulations across various therapeutic segments. It serves both domestic and international markets, focusing on affordability and quality.
Company Details
Founded: 1988
Headquarters: Indore, Madhya Pradesh, India
Sector: Pharmaceuticals
Products: Tablets, Capsules, Syrups, Ointments
Market Reach: India and Exports
Promoter Details
Promoter Name
Holding (%)
Institutional Investors
12.50
Retail & Others
87.50
Syncom Formulations Share Price Target 2024
Growth Factors:
Expanding export markets.
Focus on affordable healthcare products.
Minimum Target: ₹22
Maximum Target: ₹25
Syncom Formulations Share Price Target 2025
Key Drivers:
Increased investment in R&D for new formulations.
Growth in the domestic healthcare sector.
Minimum Target: ₹28
Maximum Target: ₹32
Syncom Formulations Share Price Target 2026 to 2030
Year
Minimum Target (₹)
Maximum Target (₹)
2026
35
40
2027
42
48
2028
50
58
2029
60
72
2030
75
90
Syncom Formulations Share Price Target 2035
Long-Term Catalysts:
Entry into niche therapeutic areas.
Diversification into over-the-counter (OTC) products.
Minimum Target: ₹110
Maximum Target: ₹135
Syncom Formulations Share Price Target 2040
By 2040, Syncom Formulations is expected to leverage its market presence and innovation to achieve robust growth.
Minimum Target: ₹150
Maximum Target: ₹180
Final Thoughts
Syncom Formulations has the potential to grow steadily in the coming years, driven by its focus on affordable medicines and international expansion. However, stock performance depends on market conditions and the company’s execution of its growth plans.
Disclaimer: Stock market investments are subject to risks. Perform thorough research or consult a financial advisor before investing. For more insights, visit moneyphobia.in!
Recent Posts
Bata India Ltd. Reports Sharp Decline in Quarterly Performance Amid Negative Financial Trend - Markets Mojo
IndiGo stock drops over 2% ahead of Q4 results as investors track fuel cost impact - Moneycontrol.com
Share market news: This logistics stock with 38% return in 1 year to be in focus as company declares quarterl - India.Com
Q4 results: Ashok Leyland, Alkem Labs, Finolex Cables, 469 more on May 28 - Business Standard
Cummins India Q4 Results: Stock jumps 10% after earnings beat; Dividend payout highest ever - CNBC TV18
Asahi India Glass Surges Over 2% Ahead of Quarterly Results; Weekly Chart Shows Sharp Uptrend - HDFC Sky
Q4 results: GMR Airports, Cummins India, Physicswallah, 181 more on May 27 - Business Standard
Yuken India Ltd Reports Mixed Quarterly Results Amid Improving Financial Trend - Markets Mojo
Q4 results: IRCTC, ONGC, Siemens, AstraZeneca, JK Tyre, 273 more on May 26 - Business Standard
Strong revenue growth fails to shield India Inc margins in March quarter - The Economic Times
Q4 results 2026: RVNL to IndiGo among companies to declare Q4 results next week; check full list here - Mint
Q4 results next week: ONGC, Asian Paints, RVNL, IRCTC, Suzlon Energy, Ashok Leyland, Cummins India and more - Upstox